GRIA2 and central nervous system cancer: An alternative splicing variant of ADAR2 with low enzyme activity was finally proven to be the reason for this, and it is dominantly expressed in gliomas and causes the reduced RNA editing of the GluA2 subunit at the glutamine/arginine site in glioma (Wei et al., 2014; Li et al., 2015).